Cargando…

Chronic Atopic Dermatitis with Eosinophilia Improved by Daesiho-Tang: A Case Report

PURPOSE: This study is to report a case of chronic atopic dermatitis (AD) with eosinophilia, which did not respond to conventional therapy and was improved by Daesiho-tang (DSHT). PATIENTS AND METHODS: The patient visited our clinic with symptoms of atopic dermatitis including skin lesions and pruri...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Min-Cheol, Lee, Ju-Hyun, Seong, Eun-Jin, Lee, Dong-Sung, Jo, Eun-Heui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518174/
https://www.ncbi.nlm.nih.gov/pubmed/37750085
http://dx.doi.org/10.2147/CCID.S424225
Descripción
Sumario:PURPOSE: This study is to report a case of chronic atopic dermatitis (AD) with eosinophilia, which did not respond to conventional therapy and was improved by Daesiho-tang (DSHT). PATIENTS AND METHODS: The patient visited our clinic with symptoms of atopic dermatitis including skin lesions and pruritus. Based on her symptoms, DSHT was prescribed. At each visit, the Scoring Atopic Dermatitis (SCORAD), Dermatology Life Quality Index (DLQI), and accompanying systemic symptoms (ASS) were measured. Multiple Allergen Simultaneous Test (MAST) was initially performed for 108 allergens and analyzed by Western blotting using an Alternate Scoring Method (ASM) according to the specific IgE concentration. Also, peripheral blood laboratory (Lab) tests were performed three times during the patient’s visit. RESULTS: After taking DSHT, the total SCORAD score improved from 62.9 to 23.5, while the patient’s ASS also improved. The DLQI score improved from 19 to 5. The total number of eosinophils in the peripheral blood, which showed a mild increase, recovered from 17.2% (0.98 x10(3)/μL) to 4.5% (0.24 x10(3)/μL). The total IgE slightly decreased, while AST and ALT were also restored to normal ranges. CONCLUSION: Based on this case, DSHT is considered a potential alternative treatment for AD.